84 completed, 30 recruiting, 26 terminated, 22 unknown. 78 Phase 2, 56 Phase 1, 23 Not applicable, 22 Phase 3, 7 Phase 4.
Follow Hereditary Sensory and Autonomic Neuropathies: new trials by email Literature Review of Hereditary Sensory and Autonomic Neuropathies trials Research Report on Hereditary Sensory and Autonomic Neuropathies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Concurrent Training vs Soleus Push-Ups on Neurogenesis-Related Biomarkers in Diabetic Neuropathy Patients Concurrent Training, Soleus Push-ups - Diabetic Peripheral Neuropathy Type 2 | Not applicable | Not yet recruiting | Riphah International University | 99 | 2026-09-01 | 2026-06-30 |
| Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) Everolimus, Tacrolimus or Cyclosporine - Liver Allograft, Liver Diseases | Phase 3 | Recruiting | Hannover Medical School | 150 | 2026-08-19 | 2026-10-05 |
| Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points - Colon Adenocarcinoma, Stage I Colon Cancer | Recruiting | Ruijin Hospital | 392 | 2026-08-14 | 2026-09-02 | |
| Cryotherapy, PGE2, NGF Levels and Pain After Endodontic Retreatment Intracanal cryotherapy, Room-temperature saline irrigation - Asymptomatic Apical Periodontitis, Endodontic Retreatment | Not applicable | Not yet recruiting | Alanya Alaaddin Keykubat University | 100 | 2026-08-01 | 2026-07-29 |
| A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors ARV-6723, Pembrolizumab, SOC - Advanced Solid Tumor | Phase 1 / Phase 2 | Recruiting | Arvinas Inc. | 499 | 2026-07-29 | 2026-10-13 |
| Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 Inavolisib - Endometrial Cancer | Phase 2 | Not yet recruiting | National Cancer Institute, Naples | 48 | 2026-05-01 | 2026-04-13 |
| Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer Serabelisib, Sapanisertib, Fulvestrant - HR+ HER2- Breast Cancer | Phase 1 / Phase 2 | Recruiting | Faeth Therapeutics | 32 | 2026-04-22 | 2026-07-02 |
| HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia HPB-092 tablet - Relapsed and Refractory Acute Myeloid Leukemia (RR-AML) | Phase 1 | Recruiting | Hangzhou Polymed Biopharmaceuticals, Inc. | 60 | 2026-04-10 | 2026-07-23 |
| The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy DLBS1033, Placebo Comparator: Placebo + Standard Therapy - Diabetic Polyneuropathy, Peripheral Nervous System Diseases | Phase 2 / Phase 3 | Not yet recruiting | Universitas Sebelas Maret | 34 | 2026-03-01 | 2026-03-16 |
| Vitamin D, Nerve Growth Factor and Nerve Conduction Studies in Adult Male Type 2 Diabetic Neuropathy Patients nerve conduction studies, Nerve Growth Factor, 25(OH) vitamin D - Diabetic Neuropathy | Not yet recruiting | Aswan University | 57 | 2025-12-01 | 2025-11-19 | |
| A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) AZD2962 - Haematologic Neoplasms | Phase 1 | Recruiting | AstraZeneca | 72 | 2025-11-03 | 2026-03-02 |
| A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY) ROC-101 - Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease | Phase 2 | Recruiting | AllRock Bio, Inc. | 40 | 2025-10-01 | 2026-10-08 |
| 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) Retifanlimab, Chemotherapy, 9-ING-41 - Pancreatic Adenocarcinoma | Phase 1 | Recruiting | Anwaar Saeed | 12 | 2025-09-22 | 2026-09-24 |
| 24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs alpelisib (BYL719) - Vascular Anomalies, Vascular Anomaly | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 61 | 2025-08-27 | 2026-10-19 |
| A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis BGB-45035, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | BeiGene | 49 | 2025-08-21 | 2026-05-28 |
| Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors ETX-636 dose escalation, ETX-636 dose escalation in combination with fulvestrant, ETX-636 dose expansion in combination with fulvestrant - Advanced Solid Tumors, Advanced Breast Cancer | Phase 1 / Phase 2 | Recruiting | Ensem Therapeutics | 233 | 2025-06-10 | 2026-10-13 |
| Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi Single agent, adjuvant anti-PD1 therapy - Melanoma | Recruiting | John Kirkwood | 30 | 2025-02-20 | 2026-01-26 | |
| Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma Melanoma (Skin) | Recruiting | Assistance Publique - Hôpitaux de Paris | 66 | 2025-01-02 | 2025-03-18 | |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer Sapanisertib, Serabelisib, Paclitaxel - Endometrial Cancer | Phase 2 | Recruiting | Faeth Therapeutics | 40 | 2024-12-12 | 2025-12-24 |
| Diffrence in Thromboprofilaksis in Elderly Ostoepenic Hip Fractures According to Mobility Status by Genetic Analysis Gene Expression Analysis - Hip Fracture of Intertrochanteric Type, Thromboembolic Event | Not applicable | Active not recruiting | Saglik Bilimleri Universitesi | 90 | 2024-11-01 | 2025-06-05 |
Showing 20 of 185. Sign in to see all of them.
Breast Neoplasms (21) · Dysautonomia, Familial (14) · Colorectal Neoplasms (12) · Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (9) · Neoplasm Metastasis (8) · Ovarian Neoplasms (8) · Endometrial Neoplasms (7) · Melanoma (7) · Urinary Bladder, Overactive (7) · Recurrence (6) · Squamous Cell Carcinoma of Head and Neck (6) · Diabetic Neuropathies (5) · Pain (5)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (185) · Genetic Diseases, Inborn (185) · Heredodegenerative Disorders, Nervous System (185) · Nervous System Diseases (185) · Nervous System Malformations (185) · Neuromuscular Diseases (185) · Polyneuropathies (185) · Neurodegenerative Diseases (183) · Peripheral Nervous System Diseases (183) · Congenital Abnormalities (182) · Neoplasms (67) · Neoplasms by Site (54) · Pathological Conditions, Signs and Symptoms (44) · Neoplasms by Histologic Type (38) · Skin and Connective Tissue Diseases (34)
Fulvestrant (10) · Alpelisib (9) · Everolimus (8) · tanezumab (7) · Cetuximab (6) · Nerve Growth Factor (6) · Sirolimus (5) · Letrozole (4) · pembrolizumab (4) · 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (3) · Irinotecan (3) · Miransertib (3) · NVP-BKM120 (3) · PX-866 (3) · Paclitaxel (3)
NYU Langone Health (13) · Novartis Pharmaceuticals (12) · Pfizer (9) · AstraZeneca (7) · Cascadian Therapeutics Inc. (3) · Children's Hospital Medical Center, Cincinnati (3) · EMD Serono Research & Development Institute, Inc. (3) · Incyte Corporation (3) · Restorbio Inc. (3) · Aalborg University (2) · Actuate Therapeutics Inc. (2) · ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) (2) · Children's Hospital Zagreb (2) · Faeth Therapeutics (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2)
United States (102) · Spain (29) · France (25) · Italy (24) · United Kingdom (20) · Germany (19) · China (18) · Canada (17) · Netherlands (14) · Australia (13) · Japan (12) · Belgium (10) · South Korea (9) · Denmark (8) · Poland (8)
Horacio Kaufmann, MD (5) · Alejandra Gonzalez-Duarte, MD (2) · Gere Sunder-Plassmann, MD (2) · Horacio C Kaufmann, MD (2) · Slaven Abdovic, MD, PhD (2) · Xinfeng Liu, MD (2) · Ahmed Mostafa Abd-Elaziz, Lecturer (1) · Albert Assad, MD (1) · Alejandra G. Miranda-Diaz, MD, PhD (1) · Alison Klein, PhD, MHS (1)
PMID 30936738, PMID 26554876, PMID 37460782, PMID 24327518, PMID 27424289, PMID 28672195, PMID 29023494, PMID 29383130, PMID 29846250, PMID 31101621, PMID 31533931, PMID 31831767, PMID 31882719, PMID 31894292, PMID 11344264, PMID 1135616, PMID 11383973, PMID 12473512, PMID 13211501, PMID 16829550, PMID 17006758, PMID 17159456, PMID 17270453, PMID 17459549, PMID 17517356, PMID 17585224, PMID 18347911, PMID 18616962, PMID 18791076, PMID 18927158, PMID 19276232, PMID 20194584, PMID 20216060, PMID 20218790, PMID 20568658, PMID 20925384, PMID 21047224, PMID 21343523, PMID 21357874, PMID 21444653, PMID 21639796, PMID 21887102, PMID 22262746, PMID 22271716, PMID 22374129, PMID 22608666, PMID 22884182, PMID 22990349, PMID 23152677, PMID 23320132
2017 (5), 2023 (3), 2025 (3), 2008 (2), 2016 (2), 2018 (2), 2009 (1), 2015 (1), 2019 (1), P50CA062924 (1), R01AG064802 (1), R01CA176828 (1), U01CA210170 (1)